Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyTrimethaphan
Identification
- Name
- Trimethaphan
- Accession Number
- DB01116 (APRD00044)
- Type
- Small Molecule
- Groups
- Approved
- Description
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. [PubChem]
- Structure
Structure for DB01116 (Trimethaphan)
- Synonyms
- Thimethaphan
- Trimetaphan
- Trimetaphanum
- Trimethaphan
- Product Ingredients
Ingredient UNII CAS InChI Key Trimethaphan camsylate 8W556014K9 68-91-7 HALWUDBBYKMYPW-STOWLHSFSA-M - International/Other Brands
- Arfonad
- Categories
- Adjuvants, Anesthesia
- Antiadrenergic Agents, Ganglion-Blocking
- Antihypertensive Agents
- Autonomic Agents
- Cardiovascular Agents
- Cardiovascular System
- Central Nervous System Agents
- Cholinergic Agents
- Cholinergic Antagonists
- Ganglionic Blockers
- Imidazoles
- Neurotransmitter Agents
- Nicotinic Antagonists
- Peripheral Nervous System Agents
- Sulfonium Derivatives
- Vasodilator Agents
- UNII
- 6G8X656T45
- CAS number
- 7187-66-8
- Weight
- Average: 365.512
Monoisotopic: 365.168759122 - Chemical Formula
- C22H25N2OS
- InChI Key
- CHQOEHPMXSHGCL-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
- IUPAC Name
- 3,5-dibenzyl-4-oxo-8λ⁴-thia-3,5-diazatricyclo[6.3.0.0²,⁶]undecan-8-ylium
- SMILES
- O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
Pharmacology
- Indication
For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.
- Structured Indications
- Not Available
- Pharmacodynamics
Trimethaphan is indicated for production of controlled hypotension during surgery to reduce bleeding into the surgical field and also for rapid reduction of blood pressure in the treatment of hypertensive emergencies, especially in patients with acute dissecting aneurysm, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.
- Mechanism of action
Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic receptors by competing with acetylcholine for these receptor sites. Additional effects may include direct peripheral vasodilation and release of histamine. Trimethaphan's hypotensive effect is due to reduction in sympathetic tone and vasodilation, and is primarily postural.
Target Actions Organism ANeuronal acetylcholine receptor subunit alpha-10 antagonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The therapeutic efficacy of Trimethaphan can be decreased when used in combination with 1,10-Phenanthroline. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Trimethaphan. Experimental Acebutolol Trimethaphan may increase the hypotensive activities of Acebutolol. Approved Aclidinium Aclidinium may increase the anticholinergic activities of Trimethaphan. Approved Alcuronium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Alcuronium. Experimental Alfentanil The risk or severity of adverse effects can be increased when Trimethaphan is combined with Alfentanil. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Trimethaphan. Approved, Investigational Aliskiren Trimethaphan may increase the hypotensive activities of Aliskiren. Approved, Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Alphaprodine. Illicit Alprenolol Trimethaphan may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Ambenonium The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ambenonium. Approved Ambrisentan Trimethaphan may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amifostine Trimethaphan may increase the hypotensive activities of Amifostine. Approved, Investigational Amlodipine Trimethaphan may increase the hypotensive activities of Amlodipine. Approved Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Trimethaphan. Approved Atenolol Trimethaphan may increase the hypotensive activities of Atenolol. Approved Atracurium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Atracurium. Experimental Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Trimethaphan. Approved, Vet Approved Benactyzine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Benactyzine. Withdrawn Benazepril Trimethaphan may increase the hypotensive activities of Benazepril. Approved, Investigational Bendroflumethiazide The serum concentration of Bendroflumethiazide can be increased when it is combined with Trimethaphan. Approved Benmoxin Benmoxin may increase the hypotensive activities of Trimethaphan. Withdrawn Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Trimethaphan. Approved Bepridil Trimethaphan may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Trimethaphan may increase the hypotensive activities of Betaxolol. Approved Bethanidine Bethanidine may increase the hypotensive activities of Trimethaphan. Approved Bezitramide The risk or severity of adverse effects can be increased when Trimethaphan is combined with Bezitramide. Experimental, Illicit, Withdrawn Bietaserpine Trimethaphan may increase the hypotensive activities of Bietaserpine. Experimental Bimatoprost Trimethaphan may increase the hypotensive activities of Bimatoprost. Approved, Investigational Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Trimethaphan. Approved Bisoprolol Trimethaphan may increase the hypotensive activities of Bisoprolol. Approved Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Trimethaphan. Experimental Bosentan Bosentan may increase the hypotensive activities of Trimethaphan. Approved, Investigational Botulinum Toxin Type A Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type B. Approved BQ-123 Trimethaphan may increase the hypotensive activities of BQ-123. Investigational Bretylium Trimethaphan may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Trimethaphan. Approved Brofaromine Brofaromine may increase the hypotensive activities of Trimethaphan. Experimental Bupranolol Trimethaphan may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Butorphanol. Approved, Illicit, Vet Approved Cadralazine Trimethaphan may increase the hypotensive activities of Cadralazine. Experimental Cafedrine Trimethaphan may increase the hypotensive activities of Cafedrine. Investigational Candesartan Trimethaphan may increase the hypotensive activities of Candesartan. Approved Candoxatril Trimethaphan may increase the hypotensive activities of Candoxatril. Experimental Captopril Trimethaphan may increase the hypotensive activities of Captopril. Approved Carfentanil The risk or severity of adverse effects can be increased when Trimethaphan is combined with Carfentanil. Illicit, Vet Approved Caroxazone Caroxazone may increase the hypotensive activities of Trimethaphan. Withdrawn Carteolol Trimethaphan may increase the hypotensive activities of Carteolol. Approved Carvedilol Trimethaphan may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Trimethaphan may increase the hypotensive activities of Celiprolol. Approved, Investigational Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Trimethaphan. Approved, Vet Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Chlorphenoxamine. Withdrawn Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Trimethaphan. Approved Cicletanine Trimethaphan may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Trimethaphan may increase the hypotensive activities of Cilazapril. Approved Cimetropium Trimethaphan may increase the anticholinergic activities of Cimetropium. Experimental Clonidine Clonidine may increase the hypotensive activities of Trimethaphan. Approved Cloranolol Trimethaphan may increase the hypotensive activities of Cloranolol. Experimental Codeine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Codeine. Approved, Illicit Coumaphos The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Coumaphos. Vet Approved Cryptenamine Trimethaphan may increase the hypotensive activities of Cryptenamine. Approved Cyclopenthiazide The serum concentration of Cyclopenthiazide can be increased when it is combined with Trimethaphan. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trimethaphan. Approved Cyclothiazide Trimethaphan may increase the hypotensive activities of Cyclothiazide. Approved Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan. Approved, Investigational Debrisoquin Trimethaphan may increase the hypotensive activities of Debrisoquin. Approved Decamethonium The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Decamethonium. Approved Delapril Trimethaphan may increase the hypotensive activities of Delapril. Experimental Demecarium The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Demecarium. Approved Deserpidine Trimethaphan may increase the hypotensive activities of Deserpidine. Approved Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethaphan. Approved, Investigational Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Trimethaphan. Withdrawn Dextromoramide The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dezocine. Approved Diazoxide Diazoxide may increase the hypotensive activities of Trimethaphan. Approved Dichlorvos The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Dichlorvos. Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan. Approved diethylnorspermine Trimethaphan may increase the hypotensive activities of diethylnorspermine. Investigational Dihydralazine Trimethaphan may increase the hypotensive activities of Dihydralazine. Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydromorphine. Experimental, Illicit Diltiazem Trimethaphan may increase the hypotensive activities of Diltiazem. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Trimethaphan is combined with Diphenoxylate. Approved, Illicit Distigmine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Distigmine. Experimental Donepezil The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Donepezil. Approved Dorzolamide Trimethaphan may increase the hypotensive activities of Dorzolamide. Approved Doxazosin Doxazosin may increase the hypotensive activities of Trimethaphan. Approved DPDPE The risk or severity of adverse effects can be increased when Trimethaphan is combined with DPDPE. Investigational Dronabinol Trimethaphan may increase the tachycardic activities of Dronabinol. Approved, Illicit Echothiophate The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Echothiophate. Approved Edrophonium The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Edrophonium. Approved Efonidipine Trimethaphan may increase the hypotensive activities of Efonidipine. Approved Eluxadoline Trimethaphan may increase the constipating activities of Eluxadoline. Approved Emepronium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Emepronium. Experimental Enalapril Trimethaphan may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Trimethaphan may increase the hypotensive activities of Enalaprilat. Approved Endralazine Trimethaphan may increase the hypotensive activities of Endralazine. Experimental Epanolol Trimethaphan may increase the hypotensive activities of Epanolol. Experimental Epoprostenol Trimethaphan may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Trimethaphan may increase the hypotensive activities of Eprosartan. Approved Etanautine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Etanautine. Experimental Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Trimethaphan. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Ethylmorphine. Approved, Illicit Etorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Etorphine. Illicit, Vet Approved Etybenzatropine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Etybenzatropine. Experimental Felodipine Trimethaphan may increase the hypotensive activities of Felodipine. Approved, Investigational Fenoldopam Trimethaphan may increase the hypotensive activities of Fenoldopam. Approved Fentanyl The risk or severity of adverse effects can be increased when Trimethaphan is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenthion The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Fenthion. Vet Approved Ferulic acid Trimethaphan may increase the hypotensive activities of Ferulic acid. Experimental Fesoterodine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine. Approved Fosinopril Trimethaphan may increase the hypotensive activities of Fosinopril. Approved Furazolidone Furazolidone may increase the hypotensive activities of Trimethaphan. Approved, Vet Approved Galantamine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Galantamine. Approved Gallamine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Gallamine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Trimethaphan. Approved Ginkgo biloba The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ginkgo biloba. Approved, Nutraceutical Glucagon recombinant The risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant. Approved Glycopyrronium Trimethaphan may increase the anticholinergic activities of Glycopyrronium. Approved, Investigational, Vet Approved Guanabenz Trimethaphan may increase the hypotensive activities of Guanabenz. Approved Guanadrel Trimethaphan may increase the hypotensive activities of Guanadrel. Approved Guanazodine Trimethaphan may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Trimethaphan may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Trimethaphan. Approved, Investigational Guanoclor Trimethaphan may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Trimethaphan may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Trimethaphan may increase the hypotensive activities of Guanoxan. Experimental Harmaline Harmaline may increase the hypotensive activities of Trimethaphan. Experimental Heroin The risk or severity of adverse effects can be increased when Trimethaphan is combined with Heroin. Approved, Illicit Hexamethonium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hexamethonium. Experimental Homatropine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Homatropine. Approved Huperzine A The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Huperzine A. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Trimethaphan. Experimental Hydralazine Trimethaphan may increase the hypotensive activities of Hydralazine. Approved Hydrochlorothiazide The serum concentration of Hydrochlorothiazide can be increased when it is combined with Trimethaphan. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone. Approved, Illicit Hydroflumethiazide The serum concentration of Hydroflumethiazide can be increased when it is combined with Trimethaphan. Approved Hydromorphone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydromorphone. Approved, Illicit Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Trimethaphan. Approved Iloprost Iloprost may increase the hypotensive activities of Trimethaphan. Approved, Investigational Imidapril Trimethaphan may increase the hypotensive activities of Imidapril. Investigational Indapamide The serum concentration of Indapamide can be increased when it is combined with Trimethaphan. Approved Indenolol Trimethaphan may increase the hypotensive activities of Indenolol. Withdrawn Indoramin Trimethaphan may increase the hypotensive activities of Indoramin. Withdrawn Ipidacrine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ipidacrine. Experimental Ipratropium bromide The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan. Approved Iproclozide Iproclozide may increase the hypotensive activities of Trimethaphan. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Trimethaphan. Withdrawn Irbesartan Trimethaphan may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Trimethaphan. Approved Isoflurophate The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Isoflurophate. Approved, Withdrawn Isradipine Trimethaphan may increase the hypotensive activities of Isradipine. Approved Itopride The therapeutic efficacy of Itopride can be decreased when used in combination with Trimethaphan. Investigational Ketanserin Trimethaphan may increase the hypotensive activities of Ketanserin. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Ketobemidone. Approved Labetalol Trimethaphan may increase the hypotensive activities of Labetalol. Approved Lacidipine Trimethaphan may increase the hypotensive activities of Lacidipine. Approved Latanoprost Trimethaphan may increase the hypotensive activities of Latanoprost. Approved, Investigational Lercanidipine Trimethaphan may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Trimethaphan is combined with Levomethadyl Acetate. Approved Levorphanol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Levorphanol. Approved Linsidomine Trimethaphan may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Trimethaphan may increase the hypotensive activities of Lisinopril. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Trimethaphan is combined with Lofentanil. Illicit Lofexidine Trimethaphan may increase the hypotensive activities of Lofexidine. Approved, Investigational Losartan Trimethaphan may increase the hypotensive activities of Losartan. Approved Macitentan Trimethaphan may increase the hypotensive activities of Macitentan. Approved Malathion The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Malathion. Approved, Investigational Manidipine Trimethaphan may increase the hypotensive activities of Manidipine. Approved Mazaticol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Mazaticol. Experimental Mebanazine Mebanazine may increase the hypotensive activities of Trimethaphan. Withdrawn Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Trimethaphan. Approved Mefloquine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mefloquine. Approved Memantine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Memantine. Approved, Investigational Meptazinol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Meptazinol. Experimental Methadone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadyl Acetate. Approved, Illicit Methanesulfonyl Fluoride The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Methanesulfonyl Fluoride. Investigational Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Trimethaphan. Approved Methoserpidine Trimethaphan may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Trimethaphan. Approved Methyl salicylate The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Methyl salicylate. Approved, Vet Approved Methyldopa Trimethaphan may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Trimethaphan. Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Trimethaphan. Approved, Investigational Metipranolol Trimethaphan may increase the hypotensive activities of Metipranolol. Approved Metixene The risk or severity of adverse effects can be increased when Trimethaphan is combined with Metixene. Approved Metoclopramide The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Metoclopramide. Approved, Investigational Metolazone The serum concentration of Metolazone can be increased when it is combined with Trimethaphan. Approved Metoprolol Trimethaphan may increase the hypotensive activities of Metoprolol. Approved, Investigational Metyrosine Trimethaphan may increase the hypotensive activities of Metyrosine. Approved Mianserin Mianserin may increase the anticholinergic activities of Trimethaphan. Approved Mibefradil Trimethaphan may increase the hypotensive activities of Mibefradil. Withdrawn Minaprine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Minaprine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Trimethaphan. Approved Mirabegron The risk or severity of adverse effects can be increased when Trimethaphan is combined with Mirabegron. Approved Mirodenafil Mirodenafil may increase the antihypertensive activities of Trimethaphan. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Trimethaphan. Approved Moexipril Trimethaphan may increase the hypotensive activities of Moexipril. Approved Molsidomine Molsidomine may increase the hypotensive activities of Trimethaphan. Approved Morphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine. Approved, Investigational Moxonidine Trimethaphan may increase the hypotensive activities of Moxonidine. Approved Muzolimine Trimethaphan may increase the hypotensive activities of Muzolimine. Experimental Nabilone Trimethaphan may increase the tachycardic activities of Nabilone. Approved, Investigational Nadolol Trimethaphan may increase the hypotensive activities of Nadolol. Approved Naftopidil Trimethaphan may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Nalbuphine. Approved Nebivolol Trimethaphan may increase the hypotensive activities of Nebivolol. Approved, Investigational Neostigmine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Neostigmine. Approved, Vet Approved Nialamide Nialamide may increase the hypotensive activities of Trimethaphan. Withdrawn Nicardipine Trimethaphan may increase the hypotensive activities of Nicardipine. Approved Nicomorphine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Nicomorphine. Experimental Nicorandil Trimethaphan may increase the hypotensive activities of Nicorandil. Approved Niguldipine Trimethaphan may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Trimethaphan may increase the hypotensive activities of Nilvadipine. Approved Nimodipine Trimethaphan may increase the hypotensive activities of Nimodipine. Approved Nisoldipine Trimethaphan may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Trimethaphan may increase the hypotensive activities of Nitrendipine. Approved Nitroprusside Nitroprusside may increase the hypotensive activities of Trimethaphan. Approved Normethadone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Normethadone. Approved, Illicit Obinutuzumab Trimethaphan may increase the hypotensive activities of Obinutuzumab. Approved Octamoxin Octamoxin may increase the hypotensive activities of Trimethaphan. Withdrawn Olmesartan Trimethaphan may increase the hypotensive activities of Olmesartan. Approved, Investigational Omapatrilat Trimethaphan may increase the hypotensive activities of Omapatrilat. Investigational Opium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Opium. Approved, Illicit Orphenadrine The risk or severity of adverse effects can be increased when Orphenadrine is combined with Trimethaphan. Approved Otilonium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Otilonium. Experimental Oxitropium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxitropium. Investigational Oxprenolol Trimethaphan may increase the hypotensive activities of Oxprenolol. Approved Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxymorphone. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Trimethaphan. Approved Pancuronium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pancuronium. Approved Paraoxon The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Paraoxon. Experimental Pargyline Pargyline may increase the hypotensive activities of Trimethaphan. Approved Penbutolol Trimethaphan may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine. Approved, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Trimethaphan. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Trimethaphan. Approved, Investigational Perindopril Trimethaphan may increase the hypotensive activities of Perindopril. Approved Pethidine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Phenazocine. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Trimethaphan. Approved Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Trimethaphan. Experimental Pheniprazine Pheniprazine may increase the hypotensive activities of Trimethaphan. Withdrawn Phenoperidine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Phenoperidine. Experimental Phenoxybenzamine Trimethaphan may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Trimethaphan. Withdrawn Phentolamine Trimethaphan may increase the hypotensive activities of Phentolamine. Approved Physostigmine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Physostigmine. Approved Pinacidil Trimethaphan may increase the hypotensive activities of Pinacidil. Withdrawn Pindolol Trimethaphan may increase the hypotensive activities of Pindolol. Approved Pipecuronium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium. Approved Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan. Approved Piritramide The risk or severity of adverse effects can be increased when Trimethaphan is combined with Piritramide. Investigational Pirlindole Pirlindole may increase the hypotensive activities of Trimethaphan. Approved Pivhydrazine Pivhydrazine may increase the hypotensive activities of Trimethaphan. Withdrawn Polythiazide The serum concentration of Polythiazide can be increased when it is combined with Trimethaphan. Approved Potassium Chloride Trimethaphan may increase the ulcerogenic activities of Potassium Chloride. Approved, Withdrawn Pramlintide Pramlintide may increase the anticholinergic activities of Trimethaphan. Approved, Investigational Prazosin Prazosin may increase the hypotensive activities of Trimethaphan. Approved Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Trimethaphan. Approved Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Trimethaphan. Approved Propiverine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Propiverine. Investigational Propranolol Trimethaphan may increase the hypotensive activities of Propranolol. Approved, Investigational Pyridostigmine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Pyridostigmine. Approved Quinapril Trimethaphan may increase the hypotensive activities of Quinapril. Approved, Investigational Quinethazone The serum concentration of Quinethazone can be increased when it is combined with Trimethaphan. Approved Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Trimethaphan. Approved Quinine Quinine may increase the hypotensive activities of Trimethaphan. Approved Ramipril Trimethaphan may increase the hypotensive activities of Ramipril. Approved Ramosetron Trimethaphan may increase the constipating activities of Ramosetron. Approved Rasagiline Rasagiline may increase the hypotensive activities of Trimethaphan. Approved Remifentanil The risk or severity of adverse effects can be increased when Trimethaphan is combined with Remifentanil. Approved Remikiren Trimethaphan may increase the hypotensive activities of Remikiren. Approved Rescinnamine Trimethaphan may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Trimethaphan. Approved Rilmenidine Trimethaphan may increase the hypotensive activities of Rilmenidine. Investigational Riociguat Trimethaphan may increase the hypotensive activities of Riociguat. Approved Rituximab Trimethaphan may increase the hypotensive activities of Rituximab. Approved Rivastigmine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Rivastigmine. Approved, Investigational Safrazine Safrazine may increase the hypotensive activities of Trimethaphan. Withdrawn Saprisartan Trimethaphan may increase the hypotensive activities of Saprisartan. Experimental Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan. Approved Scopolamine butylbromide The risk or severity of adverse effects can be increased when Trimethaphan is combined with Scopolamine butylbromide. Approved, Vet Approved Secretin The therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan. Approved, Investigational Selegiline Selegiline may increase the hypotensive activities of Trimethaphan. Approved, Investigational, Vet Approved Selexipag Trimethaphan may increase the hypotensive activities of Selexipag. Approved Sildenafil Sildenafil may increase the antihypertensive activities of Trimethaphan. Approved, Investigational Sitaxentan Trimethaphan may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Solifenacin The risk or severity of adverse effects can be increased when Trimethaphan is combined with Solifenacin. Approved Spirapril Trimethaphan may increase the hypotensive activities of Spirapril. Approved Sufentanil The risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil. Approved, Investigational Sulpiride The therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimethaphan. Approved Tacrine The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Tacrine. Withdrawn Tadalafil Tadalafil may increase the antihypertensive activities of Trimethaphan. Approved, Investigational Talinolol Trimethaphan may increase the hypotensive activities of Talinolol. Investigational Tapentadol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tapentadol. Approved Telmisartan Trimethaphan may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Trimethaphan may increase the hypotensive activities of Temocapril. Experimental, Investigational Terlipressin Trimethaphan may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Trimethaphan may increase the hypotensive activities of Tetrahydropalmatine. Investigational Theodrenaline Trimethaphan may increase the hypotensive activities of Theodrenaline. Investigational Tibolone Trimethaphan may increase the hypotensive activities of Tibolone. Approved Ticrynafen Trimethaphan may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tilidine. Experimental Timolol Trimethaphan may increase the hypotensive activities of Timolol. Approved Tiotropium Trimethaphan may increase the anticholinergic activities of Tiotropium. Approved Tolazoline Trimethaphan may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolonidine Trimethaphan may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Trimethaphan. Approved Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Trimethaphan. Approved, Investigational Topiramate The risk or severity of adverse effects can be increased when Trimethaphan is combined with Topiramate. Approved Torasemide Trimethaphan may increase the hypotensive activities of Torasemide. Approved Tramadol The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol. Approved, Investigational Trandolapril Trimethaphan may increase the hypotensive activities of Trandolapril. Approved Trans-2-Phenylcyclopropylamine Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimethaphan. Experimental Tranylcypromine Tranylcypromine may increase the hypotensive activities of Trimethaphan. Approved Travoprost Trimethaphan may increase the hypotensive activities of Travoprost. Approved Treprostinil Trimethaphan may increase the hypotensive activities of Treprostinil. Approved, Investigational Trichlorfon The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Trichlorfon. Vet Approved Trichlormethiazide The serum concentration of Trichlormethiazide can be increased when it is combined with Trimethaphan. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Trimethaphan. Approved Trimazosin Trimethaphan may increase the hypotensive activities of Trimazosin. Experimental Tropatepine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tropatepine. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Trimethaphan. Approved Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Trimethaphan. Approved Tubocurarine The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tubocurarine. Approved Udenafil Udenafil may increase the antihypertensive activities of Trimethaphan. Approved, Investigational Umeclidinium Umeclidinium may increase the anticholinergic activities of Trimethaphan. Approved Unoprostone Trimethaphan may increase the hypotensive activities of Unoprostone. Approved Urapidil Trimethaphan may increase the hypotensive activities of Urapidil. Investigational Valsartan Trimethaphan may increase the hypotensive activities of Valsartan. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Trimethaphan. Approved Vecuronium The risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium. Approved Vincamine Trimethaphan may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Trimethaphan may increase the hypotensive activities of Vinpocetine. Investigational Xipamide Trimethaphan may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Trimethaphan may increase the hypotensive activities of Xylometazoline. Approved Yohimbine Yohimbine may decrease the antihypertensive activities of Trimethaphan. Approved, Vet Approved Zofenopril Trimethaphan may increase the hypotensive activities of Zofenopril. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
- Not Available
- General References
- Not Available
- External Links
- ATC Codes
- C02BA01 — Trimetaphan
- AHFS Codes
- Not Available
- PDB Entries
- Not Available
- FDA label
- Not Available
- MSDS
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available BMI >30 kg/m2 / Hypertensive 1 1 Completed Not Available Endothelial Dysfunction 1 1 Completed Diagnostic BMI >30 kg/m2 / Hypertensive / Progressive autonomic failure / Shy-Drager Syndrome 1 1 Recruiting Not Available Hypertensive 1 1 Recruiting Basic Science Insulin Resistance 1 1 Recruiting Basic Science Idiopathic orthostatic hypotension / Multiple System Atrophy (MSA) / Supine Hypertension 1 1 Recruiting Other Hypertension,Essential / Hypertensive 1 Not Available Completed Not Available BMI >30 kg/m2 1 Not Available Completed Not Available Hypertensive / Progressive autonomic failure 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 3.473 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00665 mg/mL ALOGPS logP 4.4 ALOGPS logP 2.32 ChemAxon logS -4.8 ALOGPS pKa (Strongest Basic) -2 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 23.55 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 105.43 m3·mol-1 ChemAxon Polarizability 40.13 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9641 Blood Brain Barrier + 0.9897 Caco-2 permeable - 0.5053 P-glycoprotein substrate Substrate 0.6942 P-glycoprotein inhibitor I Inhibitor 0.6012 P-glycoprotein inhibitor II Non-inhibitor 0.6356 Renal organic cation transporter Inhibitor 0.6812 CYP450 2C9 substrate Non-substrate 0.7161 CYP450 2D6 substrate Non-substrate 0.6162 CYP450 3A4 substrate Non-substrate 0.5152 CYP450 1A2 substrate Non-inhibitor 0.5223 CYP450 2C9 inhibitor Inhibitor 0.5 CYP450 2D6 inhibitor Inhibitor 0.5134 CYP450 2C19 inhibitor Inhibitor 0.7361 CYP450 3A4 inhibitor Non-inhibitor 0.8947 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.847 Ames test Non AMES toxic 0.6511 Carcinogenicity Non-carcinogens 0.9545 Biodegradation Not ready biodegradable 0.9606 Rat acute toxicity 2.3658 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.597 hERG inhibition (predictor II) Inhibitor 0.7575
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as thienoimidazolidines. These are heterocyclic compounds containing a thiophene ring fused to an imidazolidine ring. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Imidazolidine is 5-membered saturated ring of three carbon atoms, and two nitrogen centers at the 1- and 3-positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Thienoimidazolidines
- Sub Class
- Not Available
- Direct Parent
- Thienoimidazolidines
- Alternative Parents
- Imidazolidinones / Benzene and substituted derivatives / Thiophenes / Thiolanes / Ureas / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives show 2 more
- Substituents
- Thienoimidazolidine / Monocyclic benzene moiety / Imidazolidinone / Benzenoid / Imidazolidine / Thiolane / Thiophene / Carbonic acid derivative / Urea / Azacycle show 10 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- sulfonium compound (CHEBI:9728)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Receptor binding
- Specific Function
- Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
- Gene Name
- CHRNA10
- Uniprot ID
- Q9GZZ6
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-10
- Molecular Weight
- 49704.295 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kurenny DE, Selyanko AA, Derkach VA, Gmiro VE, Skok VI: Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40. [PubMed:7963258]
- Loiacono R, Stephenson J, Stevenson J, Mitchelson F: Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex. Neuropharmacology. 1993 Sep;32(9):847-53. [PubMed:8232788]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Nakamura K, Koide M, Imanaga T, Ogasawara H, Takahashi M, Yoshikawa M: Prolonged neuromuscular blockade following trimetaphan infusion. A case report and in vitro study of cholinesterase inhibition. Anaesthesia. 1980 Dec;35(12):1202-7. [PubMed:7457791]
Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:53